Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Authors
Keywords
-
Journal
LANCET
Volume 402, Issue 10401, Pages 529-544
Publisher
Elsevier BV
Online
2023-06-27
DOI
10.1016/s0140-6736(23)01053-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The molecular pharmacology of glucagon agonists in diabetes and obesity
- (2023) Aaron Novikoff et al. PEPTIDES
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- (2022) Naveed Sattar et al. NATURE MEDICINE
- Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
- (2022) Ellen Conceição-Furber et al. Frontiers in Endocrinology
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
- (2022) Tamer Coskun et al. Cell Metabolism
- Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETES CARE
- The acute effect of glucagon on components of energy balance and glucose homoeostasis in adults without diabetes: a systematic review and meta-analysis
- (2022) James Frampton et al. INTERNATIONAL JOURNAL OF OBESITY
- LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
- (2022) Shweta Urva et al. LANCET
- Glucagon, from past to present: a century of intensive research and controversies
- (2022) André J Scheen et al. Lancet Diabetes & Endocrinology
- Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
- (2021) Juan P. Frias et al. DIABETES CARE
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
- (2021) Michele Schiavon et al. DIABETES OBESITY & METABOLISM
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
- (2021) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
- (2021) Martin Bossart et al. Cell Metabolism
- Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
- (2021) Valentina Pirro et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
- (2021) Ildiko Lingvay et al. LANCET
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
- (2020) Manal Abdelmalek et al. JOURNAL OF HEPATOLOGY
- Changes in Lean Mass, Absolute and Relative Muscle Strength, and Physical Performance After Gastric Bypass Surgery
- (2019) Diana L Alba et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
- (2019) Ian J Neeland et al. Lancet Diabetes & Endocrinology
- Glucagon Regulation of Energy Expenditure
- (2019) Maximilian Kleinert et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Metabolomics-guided insights on bariatric surgery versus behavioral interventions for weight loss
- (2016) Sara Tulipani et al. Obesity
- Mechanisms for the cardiovascular effects of glucagon-like peptide-1
- (2015) H. Poudyal Acta Physiologica
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now